SCM
BMY icon

Salem Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Salem Capital Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,100
Closed -$228K – 65
2016
Q2 		$228K Buy
+3,100
New +$219K 0.13% 64

Other funds holding BMY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Salem Capital Management's BMY Position: Q3 2016 in Review

Salem Capital Management sold out of Bristol-Myers Squibb (BMY) in Q3 2016, closing a stake of 3,100 shares — an estimated $228K sold.

Salem Capital Management first reported a position in BMY in Q2 2016 and held it in 1 quarter. The position peaked at $228K in Q2 2016. 1,522 funds tracked by Wall St. Rank hold BMY as of Q3 2016.

  • Salem Capital Management reported no remaining Bristol-Myers Squibb position as of Q3 2016 after selling out during the quarter.
  • Salem Capital Management sold 3,100 Bristol-Myers Squibb shares in Q3 2016, an estimated $228K.
  • Salem Capital Management first reported a position in Bristol-Myers Squibb in Q2 2016 and held it in 1 quarter.
  • Salem Capital Management's Bristol-Myers Squibb position peaked at $228K in Q2 2016.
  • 1,522 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2016.

Based on Salem Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.